In this prospective cohort of 56 hypertensive pregnant women, WCH had a prevalence of 44.6%. Only 55.4% of these women had high blood pressure (BP) with 24 hour ABPM (sustained HTN). Moreover, WCH was more prevalent in the second and third trimesters (40% and 60%, respectively) and we did not detect any WCH in pregnant patients with less than 12 weeks of gestation.
There was a statistically significant difference in WCH incidence between younger participants (≤ 30 years old) than older individuals (P = 0.041). Moreover, WCH patients were younger than hypertensive participants, which was statistically significant (P = 0.018).
Pregnancy-induced HTN is an important cause of maternal mortality and perinatal complications such as SGA, premature birth, and IUGR (
14). Hypertensive disorders of pregnancy classified as chronic HTN, gestational HTN, pre-eclampsia/eclampsia, and preeclampsia superimposed on chronic HTN are common, affecting up to 20% of pregnancies. They are associated with maternal and perinatal adverse outcomes that could be preventable by detecting and controlling BP during pregnancy (
15-
17).
The clinical importance of out-of-office BP monitoring and ABPM is well recognized in the management of HTN during pregnancy (
1,
8,
18) and its’ correlation with obstetrical adverse outcomes have been established (
19-
22). A trial of 24-hour ABPM is feasible during pregnancy and is tolerated fairly well by most patients (
8). The advocated ABPM devices are more accurate than devices used for office or home BP monitoring in pregnancy (
2). In a prospective study by Eguchi et al., ABPM was more associated with SGA outcome than office BP (
23).
Although there are inconclusive data that ABPM can predict pre-eclampsia, one recommended practice is to detect masked HTN and confirm WCH before initiating drug therapy.
The prevalence of WCH in pregnancy is about 30% - 70% (
10,
11) and it is associated with better outcomes than sustained HTN (
12). In a study by Brown et al., the overall prevalence of WCH was 32% among 241 pregnant participants and there was no significant difference in age or parity between WCH participants and true hypertensive patients (
9). In our study, WCH patients were younger than true hypertensive participants (P = 0.018) but there was no significant difference in parity between the two groups. Bellomo et al. performed ABPM in 148 pregnant women with 26 - 32 weeks of gestation that had office HTN (BP > 140/90 mmHg) and reported an about 30% prevalence of WCH in participants with higher birth weight babies in this subgroup compared to hypertensive pregnant patients detected by ABPM (
22).
In another study by Bar et al. in 60 pregnant women (17 - 20 weeks of gestation) without a prior history of HTN but with office HTN, almost 67% of the participants had WCH. Pre-eclampsia developed in 8% of this subgroup compared to 57% in the confirmed true hypertensive participants (
12).
In our study, the prevalence of WCH was 44.6% in pregnant patients without a history of HTN who had an obstetric office BP of > 140/90 mmHg.
Ten (32.3%) of hypertensive patients were only diagnosed based on average night time ABPM measurements. This could be a limitation of our study but also may represent the superiority of ABPM to home BP monitoring for detecting hypertensive patients during pregnancy. We did not have follow-up visits to record outcomes, and recruited a small number of study participants; they were important limitations to our study.
As the outcome of pregnancy is favorable in pregnant patients with WCH (except for perhaps a slight increase in pre-eclampsia incidence), it is prudent to assess BP in high-risk patients by 24-hour ABPM to identify true HTN and avoid unnecessary anti-hypertensive medications or termination of pregnancy.